Sarepta Therapeutics, Inc. (SRPT) shares climbed 6.29 percent, or $1.33, to $22.46 on Monday after the company reported positive topline three-year functional results from its Phase 3 EMBARK study evaluating ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy.
The encouraging long-term data reinforced investor confidence in the therapy's durability and clinical benefit.
The stock opened at $22.00, compared with a previous close of $21.13. Shares traded between $21.26 and $24.68 during the session. Trading volume reached approximately 5.07 million shares, above the average daily volume of about 4.08 million.
Sarepta Therapeutics' 52-week range stands at $10.42 to $120.05.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.